|
1
|
Tierney JF, Mosseri V, Stewart LA, Souhami
RL and Parmar MK: Adjuvant chemotherapy for soft-tissue sarcoma:
Review and meta-analysis of the published results of randomised
clinical trials. Br J Cancer. 72:469–475. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher
CD and Devesa SS: Incidence patterns of soft tissue sarcomas,
regardless of primary site, in the surveillance, epidemiology and
end results program, 1978–2001: An analysis of 26,758 cases. Int J
Cancer. 119:2922–2930. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
D'Angelo E and Prat J: Uterine sarcomas: A
review. Gynecol Oncol. 116:131–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Glabbeke M, van Oosterom AT,
Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J,
Santoro A, Buesa J and Tursz T: Prognostic factors for the outcome
of chemotherapy in advanced soft tissue sarcoma: An analysis of
2,185 patients treated with anthracycline-containing first-line
regimens-a European organization for research and treatment of
cancer soft tissue and bone S. J Clin Oncol. 17:150–157. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Juretic A, Spagnoli GC, Schultz-Thater E
and Sarcevic B: Cancer/testis tumour-associated antigens:
Immunohistochemical detection with monoclonal antibodies. Lancet
Oncol. 4:104–109. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikeda H, Lethé B, Lehmann F, van Baren N,
Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T and
Coulie PG: Characterization of an antigen that is recognized on a
melanoma showing partial HLA loss by CTL expressing an NK
inhibitory receptor. Immunity. 6:199–208. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ayyoub M, Taub RN, Keohan ML, Hesdorffer
M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS and
Valmori D: The frequent expression of cancer/testis antigens
provides opportunities for immunotherapeutic targeting of sarcoma.
Cancer Immun. 4:72004.PubMed/NCBI
|
|
8
|
Saito T, Wada H, Yamasaki M, Miyata H,
Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M and Doki Y: High
expression of MAGE-A4 and MHC class I antigens in tumor cells and
induction of MAGE-A4 immune responses are prognostic markers of
CHP-MAGE-A4 cancer vaccine. Vaccine. 32:5901–5907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krishnadas DK, Shusterman S, Bai F, Diller
L, Sullivan JE, Cheerva AC, George RE and Lucas KG: A phase I trial
combining decitabine/dendritic cell vaccine targeting MAGE-A1,
MAGE-A3 and NY-ESO-1 for children with relapsed or
therapy-refractory neuroblastoma and sarcoma. Cancer Immunol
Immunother. 64:1251–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Christopher DM, Fletcher JA, Pancras CW
and Hogendoorn FM: WHO Classification of tumor of Tissue and Bone.
Int. Agency Res. Cancer. 33–43. 2013.
|
|
11
|
Kurman RJ, Carcangiu ML, Herrington S and
Young RH: WHO classification of tumours Female Reproductive Organs.
Int. Agency Res. Cancer. 139–141. 2014.
|
|
12
|
Iura K, Kohashi K, Hotokebuchi Y, Ishii T,
Maekawa A, Yamada Y, Yamamoto H, Iwamoto Y and Oda Y: Cancer-testis
antigens PRAME and NY-ESO-1 correlate with tumour grade and poor
prognosis in myxoid liposarcoma. J Pathol Clin Res. 1:144–159.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hemminger JA, Toland AE, Scharschmidt TJ,
Mayerson JL, Guttridge DC and Iwenofu OH: Expression of
cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2 and CTAG2
in myxoid and round cell liposarcoma. Mod Pathol. 9:1238–1245.
2014. View Article : Google Scholar
|
|
14
|
Oba-Shinjo SM, Caballero OL, Jungbluth AA,
Rosemberg S, Old LJ, Simpson AJ and Marie SK: Cancer-testis (CT)
antigen expression in medulloblastoma. Cancer Immun. 8:1–7.
2008.
|
|
15
|
Kienstra MA, Neel HB, Strome SE and Roche
P: Identification of NY-ESO-1, MAGE-1 and MAGE-3 in head and neck
squamous cell carcinoma. Head Neck. 25:457–463. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheville JC and Roche P: MAGE-1 and MAGE-3
tumor rejection antigens in human germ cell tumors. Mod Pathol.
12:974–978. 1999.PubMed/NCBI
|
|
17
|
Haier J, Owzcareck M, Guller U, Spagnoli
GC, Bürger H, Senninger N and Kocher T: Expression of MAGE-A
cancer/testis antigens in esophageal squamous cell carcinomas.
Anticancer Res. 26:2281–2287. 2006.PubMed/NCBI
|
|
18
|
Sadanaga N, Nagashima H, Tahara K,
Yoshikawa Y and Mori M: The heterogeneous expression of MAGE-3
protein: Difference between primary lesions and metastatic lymph
nodes in gastric carcinoma. Oncol Rep. 6:975–977. 1999.PubMed/NCBI
|
|
19
|
Lee KD, Chang HK, Jo YK, Kim BS, Lee BH,
Lee YW, Lee HK, Huh MH, Min YG, Spagnoli GC and Yu TH: Expression
of the MAGE 3 gene product in squamous cell carcinomas of the head
and neck. Anticancer Res. 19:5037–5042. 1999.PubMed/NCBI
|
|
20
|
Tsuneyama K, Sasaki M, Shimonishi T and
Nakanuma Y: Expression of MAGE-A3 in intrahepatic
cholangiocarcinoma and its precursor lesions. Pathol Int.
54:181–186. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hudolin T, Juretic A, Spagnoli GC, Pasini
J, Bandic D, Heberer M, Kosicek M and Cacic M: Immunohistochemical
expression of tumor antigens MAGE-A1, MAGE-A3/4 and NY-ESO-1 in
cancerous and benign prostatic tissue. Prostate. 66:13–18. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Resnick MB, Sabo E, Kondratev S, Kerner H,
Spagnoli GC and Yakirevich E: Cancer-testis antigen expression in
uterine malignancies with an emphasis on carcinosarcomas and
papillary serous carcinomas. Int J Cancer. 101:190–195. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kocher T, Zheng M, Bolli M, Simon R,
Forster T, Schultz-Thater E, Remmel E, Noppen C, Schmid U,
Ackermann D, et al: Prognostic relevance of MAGE-A4 tumor antigen
expression in transitional cell carcinoma of the urinary bladder: A
tissue microarray study. Int J Cancer. 100:702–705. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sarcevic B, Spagnoli GC, Terracciano L,
Schultz-Thater E, Heberer M, Gamulin M, Krajina Z, Oresic T,
Separovic R and Juretic A: Expression of cancer/testis tumor
associated antigens in cervical squamous cell carcinoma. Oncology.
64:443–449. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bandić D, Juretić A, Sarcević B, Separović
V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D and Samija
M: Expression and possible prognostic role of MAGE-A4, NY-ESO-1 and
HER-2 antigens in women with relapsing invasive ductal breast
cancer: Retrospective immunohistochemical study. Croat Med J.
47:32–41. 2006.PubMed/NCBI
|
|
26
|
Montoro JR, Mamede RC, Neder Serafini L,
Saggioro FP, Figueiredo DL, Silva WA Jr, Jungbluth AA, Spagnoli GC
and Zago MA: Expression of cancer-testis antigens MAGE-A4 and
MAGE-C1 in oral squamous cell carcinoma. Head Neck. 34:1123–1128.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen YT, Ross DS, Chiu R, Zhou XK, Chen
YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O and Neville AM:
Multiple cancer/testis antigens are preferentially expressed in
hormone-receptor negative and high-grade breast cancers. PLoS One.
6:e178762011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Velazquez EF, Jungbluth AA, Yancovitz M,
Gnjatic S, Adams S, O'Neill D, Zavilevich K, Albukh T, Christos P,
Mazumdar M, et al: Expression of the cancer/testis antigen NY-ESO-1
in primary and metastatic malignant melanoma (MM)-correlation with
prognostic factors. Cancer Immun. 7:112007.PubMed/NCBI
|
|
29
|
Laban S, Atanackovic D, Luetkens T, Knecht
R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A,
et al: Simultaneous cytoplasmic and nuclear protein expression of
melanoma antigen-A family and NY-ESO-1 cancer-testis antigens
represents an independent marker for poor survival in head and neck
cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
John T, Starmans MH, Chen YT, Russell PA,
Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P,
et al: The role of Cancer-Testis antigens as predictive and
prognostic markers in non-small cell lung cancer. PLoS One.
8:e678762013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kao CS, Badve SS and Ulbright TM: The
utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the
diagnosis of spermatocytic seminoma. Histopathology. 65:35–44.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou X, Yang F, Zhang T, Zhuang R, Sun Y,
Fang L, Zhang C, Ma Y, Huang G, Ma F, et al: Heterogeneous
expression of CT10, CT45 and GAGE7 antigens and their prognostic
significance in human breast Carcinoma. Jpn J Clin Oncol.
43:243–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oshita C, Takikawa M, Kume A, Miyata H,
Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki
N, et al: Dendritic cell-based vaccination in metastatic melanoma
patients: Phase II clinical trial. Oncol Rep. 28:1131–1138. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kageyama S, Ikeda H, Miyahara Y, Imai N,
Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, et al:
Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced
lymphocytes in patients with recurrent esophageal cancer. Clin
Cancer Res. 21:2268–2277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Robbins PF, Morgan RA, Feldman SA, Yang
JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ,
Mackall CL, et al: Tumor regression in patients with metastatic
synovial cell sarcoma and melanoma using genetically engineered
lymphocytes reactive with NY-ESO-1. J Clin Oncol. 29:917–924. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lai JP, Robbins PF, Raffeld M, Aung PP,
Tsokos M, Rosenberg SA, Miettinen MM and Lee CC: NY-ESO-1
expression in synovial sarcoma and other mesenchymal tumors:
Significance for NY-ESO-1-based targeted therapy and differential
diagnosis. Mod Pathol. 25:854–858. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Endo M, de Graaff MA, Ingram DR, Lim S,
Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ and
Nielsen TO: NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod
Pathol. 28:587–595. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ayyoub M, Taub RN, Keohan ML, Hesdorffer
M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS and
Valmori D: The frequent expression of cancer/testis antigens
provides opportunities for immunotherapeutic targeting of sarcoma.
Cancer Immun. 4:72004.PubMed/NCBI
|
|
39
|
Laduron S, Deplus R, Zhou S, Kholmanskikh
O, Godelaine D, De Smet C, Hayward SD, Fuks F, Boon T and De Plaen
E: MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to
repress transcription. Nucleic Acids Res. 32:4340–4350. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peikert T, Specks U, Farver C, Erzurum SC
and Comhair SA: Melanoma antigen A4 is expressed in non-small cell
lung cancers and promotes apoptosis. Cancer Res. 66:4693–4700.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bhan S, Chuang A, Negi SS, Glazer CA and
Califano JA: MAGEA4 induces growth in normal oral keratinocytes by
inhibiting growth arrest and apoptosis. Oncol Rep. 28:1498–1502.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Woloszynska-Read A, Mhawech-Fauceglia P,
Yu J, Odunsi K and Karpf AR: Intertumor and intratumor NY-ESO-1
expression heterogeneity is associated with promoter-specific and
global DNA methylation status in ovarian cancer. Clin Cancer Res.
14:3283–3290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jang SJ, Soria JC, Wang L, Hassan KA,
Morice RC, Walsh GL, Hong WK and Mao L: Activation of melanoma
antigen tumor antigens occurs early in lung cancer carcinogenesis.
Cancer Res. 61:7959–7963. 2001.PubMed/NCBI
|
|
44
|
Cornejo K, Shi M and Jiang Z: Oncofetal
protein IMP3: A useful diagnostic biomarker for leiomyosarcoma. Hum
Pathol. 43:1567–1572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mueller-Pillasch F, Pohl B, Wilda M,
Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G and
Gress TM: Expression of the highly conserved RNA binding protein
KOC in embryogenesis. Mech Dev. 88:95–99. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nielsen J, Christiansen J, Lykke-Andersen
J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like
growth factor II mRNA-binding proteins represses translation in
late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI
|
